SAN DIEGO (AP) – Drug developer Trius Therapeutics Inc. received a $5 million payment from its partner Bayer Healthcare after a successful late-stage trial of an experimental skin infection treatment.
Trius said its drug tedizolid met all its goals in the study. The company said in December that tedizolid was as effective as Pfizer Inc.’s drug Zyvox in treating infections like MRSA, or methicillin-resistant Staphylococcus aureus. Such infections have become an increasing problem as they become resistant to commonly used antibiotics.
The companies started a second late-stage trial in September and results from that study are expected in early 2013. The companies plan to use the results from the studies to support applications for drug approval with the Food and Drug Administration and the European Medicines Agency.
Date: January 23, 2012
Source: Associated Press
